Listing - November 23, 2020
Pila Pharma announces plans to go public
The Swedish biotech company Pila Pharma has announced the decision to list the company. The Initial Public Offering (IPO), aiming for listing of the company’s shares on one of the unregulated stock exchanges in Sweden, is targeted for Q2-2021. To facilitate the IPO process, Göteborg Corporate Finance (GCF) has been selected as the capital finance […]
In a new job - December 7, 2017
Progress for Pila Pharma
PILA PHARMA passes the start-up phase, prepares for efficacy trials and increases focus on ‘Effective and Affordable Medicine’ by electing the health economist Ulrikka Klarskov Kjær to the Board of Directors. The company, founded in 2014, now counts +10 core members and has thus passed the “start-up” phase. “We are about to move out of […]
Profiles in Pharma - March 22, 2017
“The scientist in me wants to make a difference”
After ten years of diabetes research and development at Novo Nordisk, Dorte X. Gram took her findings and work further to start something on her own. As founder and CEO of PILA PHARMA she hopes to bring a new oral anti-diabetic agent to the market.
Clinical Trials - March 6, 2017
Regulatory approval for PILA PHARMA’s clinical trial application
PILA PHARMA has received regulatory approval of its first clinical trial application thus permitting the company to move its clinical development candidate, XEN-D0501, into a safety trial in type 2 diabetic patients. “I am very excited about finally being at the point where we can progress a TRPV1 antagonist into diabetic patients!”, says Dorte X. […]
Acquisition - April 5, 2016
Pila Pharma acquires Ario Pharma’s TRPV1 assets
The Malmö based “micro-pharma” aiming at developing innovative new approaches to treat diabetes, PILA PHARMA has acquired XEN-D0501, a clinical ready and safe TRPV1 antagonist development candidate, previously owned by Ario Pharma. The acquired asset include a series of small molecule TRPV1 antagonists including the clinical ready and safe development candidate XEN-D0501, patents, know-how and data. The TRPV1 target (also called […]
